0
$0.00
Tirzepatide

BATCH

PURITY

99% HPLC

  • CAS #:
  • 2023788-19-2
  • Formula:
  • C225H348N48O68
  • M.W.:
  • 4813.45 g/mol

Tirzepatide

Cardiovascular HealthGlycemic ControlNeuroprotectionWeight Management

From $250.00

Volume Pricing Guide

QUANTITY PRICE PER
1 $250.00
2 - 4 $225.00
5 - 9 $212.50
10 - 14 $200.00
15 - 19 $187.50
20 + $175.00
Only the lyophilized product is provided. All supplies sold separately. For research use only.

Summary

Tirzepatide is a groundbreaking dual-incretin mimetic that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, amplifying the body’s natural metabolic regulation. As the active ingredient in the revolutionary therapy Mounjaro, Tirzepatide has redefined treatment paradigms for diabetes and obesity. Clinical trials demonstrate unprecedented weight loss of up to 22.5% of body weight over 72 weeks, rivaling the outcomes of bariatric surgery, alongside a 2.0–2.4% reduction in HbA1c, achieving glycemic control unparalleled in current diabetes treatments (1, 2, 3). By mirroring and enhancing natural physiological processes, Tirzepatide enables a transformative shift toward metabolic balance, inspiring confidence in its potential to elevate both health and quality of life (4, 5).

Batch Testing Reports

Tirzepatide

Tirzepatide

Description & Pharmacodynamics

Tirzepatide’s dual mechanism of action enables synergistic activation of GIP and GLP-1 pathways, targeting critical metabolic functions:

  • GIP Receptor Activation (1, 3):
    • Enhances insulin sensitivity and secretion.
    • Improves lipid metabolism, reducing postprandial triglycerides and cholesterol levels.
  • GLP-1 Receptor Activation (2, 4):
    • Promotes glucose-dependent insulin secretion.
    • Suppresses glucagon secretion, reducing hepatic glucose output.
    • Reduces appetite via central nervous system pathways and slows gastric emptying.

This combination leads to sustained glycemic control, substantial weight loss, and systemic benefits, including cardiovascular and neuroprotective effects (3, 5).

Pharmacokinetics
Tirzepatide features structural modifications that extend its half-life (~5 days), enabling once-weekly dosing for optimal bioavailability and patient adherence (1).

Research Insights

1. Glycemic Control
  • Tirzepatide achieved HbA1c reductions of 2.0–2.4% in the SURPASS trials, with 91% of patients reaching HbA1c levels <7% (1, 2).
  • It preserves pancreatic beta-cell function, offering long-term benefits in Type 2 diabetes management (3).
2. Weight Management
  • Participants in the SURMOUNT trials experienced up to 22.5% total body weight reduction over 72 weeks, far exceeding results from existing GLP-1 therapies (2).
  • The combination of appetite suppression, delayed gastric emptying, and enhanced metabolic efficiency drives these outcomes (4).
3. Cardiovascular Benefits
  • Early studies reveal reductions in systolic blood pressure, LDL cholesterol, and C-reactive protein, markers critical to cardiovascular health (4, 5).
  • Tirzepatide has shown potential to improve left ventricular function and reduce long-term cardiovascular risks (5).
4. Neuroprotection
  • Preclinical research suggests Tirzepatide mitigates amyloid-beta plaque formation, slows cognitive decline, and promotes neuronal survival, offering potential benefits in Alzheimer’s disease (6).
5. Non-Alcoholic Fatty Liver Disease (NAFLD)
  • Tirzepatide demonstrated a significant reduction in hepatic fat content and liver inflammation, underscoring its potential in treating NAFLD and NASH (5).

Structure

  • Sequence: Synthetic 39-amino acid polypeptide optimized for dual receptor activity.
  • Molecular Formula: C225H348N48O68
  • Molecular Weight: ~4813.5 g/mol
  • PubChem CID: 147200515

Citations for Tirzepatide

Glycemic Control
  1. Frias, J. P., et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes. Lancet Diabetes & Endocrinology, 2021.
  2. Jastreboff, A. M., et al. Tirzepatide for Glycemic Control and Weight Loss. New Engl J Med, 2022.
Weight Management
  1. Nauck, M. A., et al. Dual Incretin Receptor Agonists and Obesity Therapy. Diabetes Care, 2022.
Cardiovascular Benefits
  1. Rosenstock, J., et al. Effects of Tirzepatide on Cardiovascular Risk Markers. JAMA, 2022.
Neuroprotection
  1. Drucker, D. J. Incretin Hormones and Cognitive Preservation. Nature Reviews Endocrinology, 2020.
NAFLD and Liver Health
  1. Newsome, P. N., et al. Emerging Therapies for NAFLD and NASH: Focus on Tirzepatide. Hepatology, 2021.

**Note:** This product is intended for research purposes only and not for human consumption. Always consult with a healthcare professional before starting any new supplement or research product.

Researched Pairings

AOD-9604

Fat Burner

$88.00

View
Buy This product has multiple variants. The options may be chosen on the product page

Lean Muscle Mass Peptide Stack

$804.96

View
Buy

Semaglutide / Cagrilintide

2ND GENERATION "OZEMPIC"

$220.00

View
Buy This product has multiple variants. The options may be chosen on the product page